Welcome to our dedicated page for ETRACS Whitney US Critical Techs ETN SEC filings (Ticker: WUCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for WUCT aggregates regulatory documents tied to ETRACS Whitney US Critical Technologies ETNs issued by UBS AG, a foreign private issuer. The core filings here are Forms 6-K, which provide interim financial and legal updates that are incorporated by reference into UBS AG’s Form F-3 registration statement for securities offerings.
In these Form 6-K reports, UBS AG discloses consolidated capitalization in US dollars under IFRS Accounting Standards, detailing short-term and long-term debt issued by UBS AG and its subsidiaries, funding from UBS Group AG, equity attributable to shareholders and non-controlling interests, and total capitalization. Such information helps investors understand the broader balance sheet context of the issuer behind the WUCT-linked ETNs.
The filings also explain how specific 6-K reports are incorporated into UBS AG’s Form F-3 registration statement and any outstanding prospectuses or offering circulars that reference those 6-Ks. This structure means that updates filed on Form 6-K become part of the official documentation for securities, including the ETRACS Whitney US Critical Technologies ETNs associated with WUCT.
Another Form 6-K on this page consists of the opinion of Homburger AG, acting as special Swiss counsel to UBS AG, which is filed as an exhibit to the Form F-3 registration statement and replaces a prior opinion. This highlights the role of legal opinions in UBS AG’s securities registration process.
On Stock Titan, users can access these filings in one place, with AI-powered tools available to summarize key sections, highlight important capitalization and legal disclosures, and help interpret how each new Form 6-K or related document fits into UBS AG’s overall reporting framework for the WUCT-linked ETNs.
UBS AG plans to issue $4.5 million of unsecured, unsubordinated Market-Linked Notes (Form 424B2) that mature on July 7 2026. The Notes are tied to an unequally-weighted basket of six major currencies against the U.S. dollar (EUR, JPY, GBP, CAD, SEK, CHF). Investors receive:
- Upside participation: any positive basket return × 1.20 participation rate, subject to an embedded cap derived from the 100% per-currency limit.
- Downside protection limited to –5.00%: if the basket return is ≤0, repayment equals the greater of the basket return or the −5.00% minimum, so principal loss is capped at 5%.
Key terms include a $1,000 issue price, CUSIP 90308V4P3, and a minimum maturity payment of $950. The estimated initial value is $983, reflecting dealer margins and UBS’s internal funding rate. Settlement is T+3 (June 25 2025), with JP Morgan Securities acting as placement agent (underwriting fee $10 per Note).
Risks: the Notes pay no coupons, are not listed, may trade at a discount, and are exposed to both basket performance and UBS credit risk. UBS is not obligated to repay full principal; investors could lose up to 5% and face liquidity constraints. The filing stresses that the product suits investors who understand structured currency exposure, can hold to maturity, and accept limited downside protection.
Offering overview: UBS AG is marketing unsubordinated, unsecured Trigger Callable Contingent Yield Notes maturing on or about July 1, 2027. The Notes are linked to the least-performing of the Nasdaq-100, Russell 2000 and S&P 500 indices and will be sold in $1,000 denominations.
Key economic terms:
- Contingent coupon: 10.30% per annum (paid monthly) if, on the relevant observation date, every underlying index closes at or above its 70% coupon barrier.
- Issuer call: UBS may redeem the Notes in whole on any monthly observation date beginning after three months; payment equals principal plus the contingent coupon due.
- Downside protection: At maturity, full principal is repaid only if each index closes at or above its 60% downside threshold. Otherwise, investors incur a loss proportionate to the worst-performing index, up to 100% of principal.
- Estimated initial value: $945.10–$975.10 per $1,000 Note, reflecting internal pricing models and funding costs.
- Underwriting discount: $6.50 per Note; net proceeds to UBS approximately $993.50 per Note.
- Key dates: Trade Date – Jun 27 2025; Settlement Date – Jul 2 2025; Final Valuation Date – Jun 28 2027; Maturity Date – Jul 1 2027.
Principal risks highlighted by UBS: (1) loss of some or all principal if any index breaches its 60% threshold, (2) possibility of no coupons during the term, (3) exposure to the worst-performing index without offset, (4) discretionary early call by UBS, (5) credit risk of UBS, and (6) limited liquidity—Notes will not be exchange-listed.
The offering documents (prospectus, index supplement and product supplement each dated Feb 6 2025) have been filed with the SEC under registration statement 333-283672.